ECM buys urology specialist Uroviva

ECM drew equity for the transaction from German Equity Partners IV, a €230m buyout fund that was 60% deployed as of April 2017, according to unquote" data.

GEP IV generally takes majority stakes in companies with enterprise values between €20-100m.

The previous shareholders – medical doctors Roger Gablinger, Michael Krause and Ladislav Prikler – will remain in their management positions and retain a stake.

ECM identifies an aging population and growing awareness of health and wellbeing as drivers behind the growth in demand for urological and andrological treatments.

Uroviva plans to open further clinics and expand the medical team. Two new practice locations are scheduled for 2018.

Company
Headquartered in Bülach, Uroviva is a Swiss urologist with eight urological practices and one andrological practice under construction. A team of 21 urologists performs 26,000 treatments per year.

People
ECM Equity Capital Management – Florian Kähler (managing director); Alexander Schönborn (investment director); Marius Buxkämper, Max Thielemann (investment managers); Benedikt Müller (investment associate).
Uroviva Group – Roger Gablinger, Michael Krause, Ladislav Prikler (partners).

Advisers
Equity – Milbank Tweed Hadley & McCloy (legal); Homburger (legal); Goetzpartners (commercial due diligence); EY (financial due diligence, tax); Willis Towers Watson (insurance due diligence).
Company – Affentranger Associates (corporate finance); Vialex (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Healthcare
• Switzerland
• ECM Equity Capital Management